Search Results - "Pontikaki, I."

Refine Results
  1. 1

    Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients by Gerloni, V, Pontikaki, I, Gattinara, M, Fantini, F

    Published in Annals of the rheumatic diseases (01-08-2008)
    “…To report adverse events (AEs) seen in a large cohort of patients with juvenile idiopathic arthritis (JIA) treated with tumour necrosis factor (TNF)alpha…”
    Get more information
    Journal Article
  2. 2

    Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases by Miserocchi, E, Pontikaki, I, Modorati, G, Gattinara, M, Meroni, P.L, Gerloni, V

    Published in Autoimmunity reviews (01-11-2011)
    “…Abstract Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells and widely used in the treatment of non-Hodgkin's lymphoma…”
    Get full text
    Journal Article
  3. 3

    Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients by Romano, M, Pontikaki, I, Gattinara, M, Ardoino, I, Donati, C, Boracchi, P, Meroni, P L, Gerloni, V

    Published in Reumatismo (17-03-2014)
    “…The objective of this study was to determine long-term effectiveness and safety of 1st biological treatment (BT) in a cohort of 301 juvenile idiopathic…”
    Get full text
    Journal Article
  4. 4

    Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10‐year prospective study by Gerloni, V., Cimaz, R., Gattinara, M., Arnoldi, C., Pontikaki, I., Fantini, F.

    Published in Rheumatology (Oxford, England) (01-08-2001)
    “…Objective. This open prospective trial was performed in order to assess the efficacy and safety of cyclosporin A in the treatment of patients with juvenile…”
    Get full text
    Journal Article
  5. 5

    Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience by Gerloni, V., Pontikaki, I., Gattinara, M, Fantini, F.

    Published in Reumatismo (12-09-2011)
    “…The therapeutic approach to JIA is sometimes very troublesome and progression to erosive polyarthritis may occur in all JIA categories. Only Methotrexate has…”
    Get full text
    Journal Article
  6. 6

    Primary Sjögren syndrome: report of a 10 years old girl with local edema and positivity of anti SS-A and anti SS-B autoantibodies by Shahi, E, Donati, C, Gattinara, M, Pontikaki, I, Gerloni, V

    Published in Reumatismo (12-09-2011)
    “…Sjogren-Larsson syndrome (SLS) is an autoimmune disease, uncommon in childhood. We report a case of SLS in a 10-year-old girl with a history of tumor, calor…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10

    Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy by De Marco, G, Gerloni, V, Pontikaki, I, Luriati, A, Teruzzi, B, Salmaso, A, Valcamonica, E, Gattinara, M, Fantini, F

    Published in Reumatismo (01-01-2007)
    “…To evaluate, in long-term open label prospective study, infliximab as therapeutic choice for Juvenile Idiopathic Arthritis (JIA) non responsive to conventional…”
    Get full text
    Journal Article
  11. 11

    Patients with juvenile idiopathic arthritis become adults: the role of transitional care by Conti, Fabrizio, Pontikaki, Irene, D'Andrea, Mariella, Ravelli, Angelo, De Benedetti, Fabrizio

    Published in Clinical and experimental rheumatology (01-11-2018)
    “…Most juvenile idiopathic arthritis (JIA) patients need to attend adult rheumatology centres to continue the clinical management of their disease and to receive…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors by Cimaz, Rolando, Cazalis, Marie-Angélique, Reynaud, Charlotte, Gerloni, Valeria, Zulian, Francesco, Biggioggero, Martina, Martini, Giorgia, Pontikaki, Irene, Fantini, Flavio, Mougin, Bruno, Miossec, Pierre

    Published in Annals of the rheumatic diseases (01-07-2007)
    “…Objective: To investigate the genetic contribution of cytokine gene polymorphisms (interleukin 1 (IL1) and tumour necrosis factor α (TNFα)) on disease…”
    Get full text
    Journal Article
  18. 18

    A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti–tumor necrosis factor α agents by Lurati, A., Pontikaki, I., Teruzzi, B., Desiati, F., Gerloni, V., Gattinara, M., Cimaz, R., Fantini, F.

    Published in Arthritis and rheumatism (01-05-2006)
    “…Objective There are no validated criteria to evaluate clinical response in juvenile idiopathic arthritis (JIA). The purpose of this study was to compare 4 sets…”
    Get full text
    Journal Article
  19. 19

    Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience by Gerloni, V, Pontikaki, I, Gattinara, M, Fantini, F

    Published in Reumatismo (01-07-2007)
    “…The therapeutic approach to JIA is sometimes very troublesome and progression to erosive polyarthritis may occur in all JIA categories. Only Methotrexate has…”
    Get full text
    Journal Article
  20. 20